

Supplementary Table 1: New active substances approved by EMA or FDA initially in 2014-2016, with approval date tracked until 2017.

Generic name	EMA Approval Year	FDA Approval Year
Albiglutide	2014	2014
albutrepenonacog alfa	2016	2016
alectinib hydrochloride	2017	2015
Alirocumab	2015	2015
allogeneic t cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (Ingfr) and the herpes simplex i virus thymidine kinase (hsv-tk mut2)	2016	
anthrax immune globulin intravenous (human)		2015
antihemophilic factor (recombinant), porcine sequence	2015	2014
apremilast	2015	2014
aripiprazole lauroxil		2015
asfotase alfa	2015	2015
ataluren	2014	
atezolizumab	2017	2016
autologous cd34+ enriched cell fraction that contains cd34+ cells transduced with retroviral vector that encodes for the human adenosine deaminase (ada) cdna sequence from human haematopoietic stem/progenitor (cd34+) cells	2016	
avibactam sodium; ceftazidime	2016	2015
belinostat		2014
betulae cortex	2016	
bezlotoxumab	2017	2016
blinatumomab	2015	2014
brexpiprazole		2015
brivaracetam	2016	2016
cangrelor	2015	2015
cariprazine hydrochloride	2017	2015
ceftolozane;tazobactam	2015	2014
ceritinib	2015	2014

coagulation factor ix (recombinant), fc fusion protein	2016	2014
cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate	2015	2015
cobimetinib	2015	2015
crisaborole		2016
crotalidae immune f(ab') ₂ (equine)		2015
daclatasvir	2014	2015
dalbavancin hydrochloride	2015	2014
daratumumab	2016	2015
delamanid	2014	
deoxycholic acid		2015
dinutuximab	2015	2015
droxidopa		2014
dulaglutide	2014	2014
edoxaban tosilate hydrate	2015	2015
efinaconazole		2014
efraloctocog alfa (genetical recombination)	2015	2014
elbasvir + grazoprevir	2016	2016
eliglustat tartrate	2015	2014
elosulfase alfa	2014	2014
elotuzumab	2016	2015
eluxadoline	2016	2015
empagliflozin	2014	2014
etelcalcetide hydrochloride	2016	2017
eteplirsen		2016
evolocumab	2015	2015
ex vivo expanded autologous human corneal epithelial cells containing stem cells	2015	
finafloxacin		2014
flibanserin		2015
florbetaben (18f)	2014	2014
fluciclovine f-18	2017	2016
idarucizumab	2015	2015
idelalisib	2014	2014
isavuconazole	2015	2015
ixazomib citrate	2016	2015
ixekizumab	2016	2016
ledipasvir; sofosbuvir	2014	2014

lenvatinib	2015	2015
lesinurad	2016	2015
lifitegrast		2016
lonococog alfa	2017	2016
lumacaftor	2015	2015
mepolizumab	2015	2015
metreleptin		2014
migalastat hydrochloride	2016	
miltefosine		2014
naloxegol	2014	2014
necitumumab	2016	2015
netupitant; palonosetron hydrochloride	2015	2014
nintedanib	2014	2014
nivolumab	2015	2014
nusinersen	2017	2016
obeticholic acid	2016	2016
obiltoxaximab		2016
olaparib	2014	2014
olaratumab	2016	2016
olodaterol hydrochloride		2014
opicapone	2016	
oritavancin diphosphate	2015	2014
osimertinib mesylate	2016	2015
palbociclib	2016	2015
panobinostat	2015	2015
patiomer sorbitex calcium	2017	2015
peginterferon beta-1a	2014	2014
pembrolizumab	2015	2014
peramivir		2014
pimavanserin tartrate		2016
pitolisant	2016	
ramucirumab	2014	2014
reslizumab	2016	2016
rolapitant hydrochloride	2017	2015
rucaparib camsylate		2016
sacubitril / valsartan	2015	2015
saquinamide	2015	2017
sebelipase alfa	2015	2015
secukinumab	2015	2015

selexipag	2016	2015
siltuximab	2014	2014
simoctocog alfa	2014	2015
sofosbuvir / velpatasvir	2016	2016
sonidegib	2015	2015
suvorexant		2014
talimogene laherparepvec	2015	2015
tasimelteon	2015	2014
tavaborole		2014
tedizolid phosphate	2015	2014
trifluridine/tipiracil hydrochloride	2016	2015
uridine triacetate		2015
vedolizumab	2014	2014
venetoclax	2016	2016
von willebrand factor (recombinant)		2015
vorapaxar sulfate	2015	2014